Research
Hormonal
Metabolic surgery (VSG/RYGB) alters gut hormone profiles by increasing GLP-1 and PYY while decreasing ghrelin, leading to reduced hunger and improved satiety, which aids in sustained weight loss and glucose control.
Surgery biologically reduces your hunger drive (ghrelin) and increases fullness signals (GLP-1/PYY), making it easier to maintain weight loss compared to dieting alone, which often triggers intense hunger.
GoodSupportsHIGH confidence
To summarize, following RYGB and VSG, there is an elevated post-prandial response involving GLP-1 and PYY with a decreased level of circulating ghrelin. GLP-1 RAs have been shown to induce weight loss and improve glycemic control; therefore, the exaggerated GLP-1 response following surgery may play a significant role in the long-term restoration of β-cell function and improved glucose homeostasis in T2DM patients.
Why this rating
Well-supported by multiple human and animal studies cited.
Source
Mechanism of metabolic surgery for the treatment of Type 2 Diabetes Mellitus (T2DM)
David J. Leishman et al. · Mini-invasive Surgery · 2023
DOI 10.20517/2574-1225.2023.29
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metabolic surgery (RYGB/VSG) improves glycemic control and induces T2DM remission through weight-loss-independent mechanisms, specifically by altering bile acid metabolism (FXR/TGR5 pathways), increasing incretin hormones (GLP-1/PYY), and modulating the gut microbiome, in addition to caloric restriction.Good
- Metabolic surgery increases circulating levels of bile acids (BAs), which activate FXR and TGR5 receptors to suppress gluconeogenesis, improve insulin resistance, and stimulate GLP-1 secretion, thereby improving glucose homeostasis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →